Eton Pharmaceuticals Announces Third Quarter 2020 Financial Results

Rhea-AI Summary

Eton Pharmaceuticals, Inc. (Nasdaq: ETON) reported Q3 2020 financial results, revealing a revenue of ($0.2) million, attributed to a price reduction of Biorphen. SG&A expenses rose to $3.4 million, while R&D expenses decreased to $2.8 million. The net loss increased to $6.5 million compared to $5.0 million a year ago. Eton successfully closed an oversubscribed equity offering raising approximately $22.5 million. Key milestones include the FDA approval of ALKINDI SPRINKLE, expected to launch by November, and four NDAs submitted with upcoming PDUFA dates in 2021.

Positive

• FDA approval of ALKINDI SPRINKLE; expected commercial availability by end of November.
• Successful completion of $22.5 million equity financing to support product launches and profitability.
• Strong initial interest in ALKINDI SPRINKLE from physicians and caregivers.
• Multiple NDAs submitted with PDUFA dates set for May and June 2021.

Negative

• Revenue reported was ($0.2) million due to a shelf stock adjustment.
• Increased SG&A expenses of $3.4 million, impacting overall financials.
• Net loss widened to $6.5 million from $5.0 million year-over-year.

DEER PARK, Ill., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases, today reported financial results for the third quarter ended September 30, 2020 and provided an update on business progress.

“In recent weeks we submitted the last of our nine product candidates to the FDA. This is a tremendous accomplishment by our team after years of hard work. We are now turning our focus to building out a leading orphan drug commercial organization,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Early interest in ALKINDI SPRINKLE from physicians and caregivers has been very strong and has reiterated the significant need for the product.”

Recent Business Milestones

• FDA approval of orphan product ALKINDI^® SPRINKLE. In September, ALKINDI SPRINKLE was approved by the FDA as a replacement therapy for Adrenocortical Insufficiency in patients under 17 years of age. Eton expects to have the product commercially available by the end of November.
  
  
• FDA approval of Alaway Preservative Free^®. During the quarter, Alaway Preservative Free was approved by the FDA. Bausch Health plans to launch the product by the Spring of 2021 and Eton will receive a royalty on sales of the product.
  
  
• Four additional NDAs submitted to the FDA. Eton, or its partners, have submitted four NDAs in the second half of 2020. Dehydrated alcohol injection, zonisamide oral suspension, and ephedrine injection have all been accepted for filing and assigned PDUFA dates of May 27, 2021; May 29, 2021; and June 18, 2021, respectively.
  
  
• Successful completion of equity financing. In October, Eton closed an oversubscribed common stock offering which resulted in gross proceeds of approximately $22.5 million. The proceeds are expected to be sufficient to allow Eton to launch its current pipeline products and reach profitability.
  

ALKINDI SPRINKLE

Eton anticipates having commercial availability of ALKINDI SPRINKLE by the end of November. The company’s ALKINDI SPRINKLE sales representatives have been hired, fully trained, and have begun engaging with pediatric endocrinologists. Initial interest from physicians, caregivers, and patients has been very strong and Eton expects the product to exceed the company’s original sales forecast for 2021.

Biorphen

The company remains on schedule to file a Prior Approval Supplement for Biorphen vials in the fourth quarter of 2020, which should allow for a launch of the vial product in the first half of 2021. Customer feedback continues to show aversion to the ampule format but strong interest in the product in vial form.

Pipeline Update

Product	Regulatory Status
Biorphen®	Commercial
ALKINDI® SPRINKLE	Approved
Alaway Preservative Free®	Approved
Dehydrated Alcohol Inj. (DS-100)	Filed
Lamotrigine Oral Susp. (ET-105)	Filed
Zonisamide Oral Susp. (ET-104)	Filed
Cysteine Inj. (DS-300)	Filed
Ephedrine Injection (ET-203)	Filed
Topiramate Oral Soln (ET-101)	Submitted

Dehydrated Alcohol Injection (DS-100). During the quarter, Eton submitted an NDA for the product and the application was accepted for filing. The application has been assigned a PDUFA date of May 27, 2021.

Lamotrigine Oral Suspension (ET-105). The product’s human factors study is ongoing. One of the three requested arms has been completed, and the two remaining arms are ongoing. Eton expects the study to be completed and submitted to the FDA in the coming months, allowing for potential FDA approval as early as the first half of 2021.

Zonisamide Oral Suspension (ET-104). During the quarter, Eton submitted an NDA for the product and the application was accepted for filing. The application has been assigned a PDUFA date of May 29, 2021.

Cysteine Injection (DS-300). In October, Eton’s Abbreviate New Drug Application received a complete response letter from the FDA with only minor deficiencies. Eton expects to respond to the request in December, which should allow the application to receive tentative approval as early as the first quarter of 2021. The company’s paragraph IV litigation and post grant review (PGR) challenges are ongoing. Eton remains confident the innovator’s patents will be invalidated, and the company believes its product could launch as early as November 2021 if the PGR process is successful or August 2022 when the 30-month stay expires.

Ephedrine Injection (ET-203). Eton’s partner submitted the product’s NDA during the quarter and the application has been accepted for filing by the FDA. The NDA has been assigned a PDUFA date of June 18, 2021.

Topiramate Oral Solution (ET-101). Eton submitted an NDA for the product in October 2020. If the application is accepted for filing, Eton would expect it to be assigned a PDUFA date of Q3 2021.

Financial Results

Revenue: Eton reported revenue of ($0.2) million for the third quarter of 2020. During the quarter, Eton lowered the list price of Biorphen, which resulted in a $0.2 million reduction to revenue due to a shelf stock adjustment charge tied to inventory on hand with wholesale customers. Eton reported no revenue in the third quarter of 2019.

Selling, General, & Administrative (SG&A): SG&A expenses in the third quarter of 2020 were $3.4 million compared with $1.6 million in the prior year period. The increase was driven by higher sales and marketing spending in advance of the ALKINDI SPRINKLE launch, paragraph IV litigation expenses related to the company’s cysteine injection patent challenge, and higher non-cash stock-based compensation in the period.

Research & Development (R&D): R&D expenses in the third quarter of 2020 were $2.8 million compared with $3.4 million in the prior year period. The third quarter of 2020 included a $1.5 million NDA filing fee paid to the FDA. The third quarter of 2019 included a $2.0 million licensing payment related to the lamotrigine product.

Net Loss: Eton reported a net loss of $6.5 million in the third quarter of 2020 compared to a net loss of $5.0 million for the same period in 2019.

Cash Position: As of September 30, 2020, Eton reported cash and cash equivalents of $7.3 million. Subsequent to the quarter end, Eton closed an equity financing which resulted in gross proceeds of approximately $22.5 million.

Conference Call and Webcast Information:
Eton Pharmaceuticals will host a conference call and webcast today at 4:30 p.m. ET (3:30 p.m. CT). To access the conference call, please dial 1-866-795-8473 (domestic) or 1-470-495-9161 (international) and refer to conference ID 5092872. The webcast can be accessed under “Events & Presentations” in the Investors section of the Company’s website at https://ir.etonpharma.com. The webcast will be archived and made available for replay on the company’s website approximately two hours after the call and will be available for 30 days.

About Eton Pharmaceuticals
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI^® SPRINKLE, Biorphen^®, and Alaway Preservative Free^®, and has six additional products that have been submitted to the FDA.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "intends," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Eton Pharmaceuticals, Inc.
Condensed Statements of Operations
(In thousands, except per share amounts)
(Unaudited)

		For the three months ended							For the nine months ended
	September 30,				September 30,				September 30,				September 30,
	2020				2019				2020				2019
Revenues:
Product sales, net	$	(161	)		$	—			$	(42	)		$	—
Licensing revenue		—				—				—				500
Total revenues		(161	)			—				(42	)			500
Cost of product sales		(144	)			—				(14	)			—
Gross (loss) profit		(17	)			—				(28	)			500
Operating expenses:
Research and development		2,826				3,418				10,703				11,322
General and administrative		3,429				1,624				8,960				5,123
Total operating expenses		6,255				5,042				19,663				16,445
Loss from operations		(6,272	)			(5,042	)			(19,691	)			(15,945	)
Other (expense) income:
Interest and other (expense) income, net		(232	)			77				(592	)			321
Loss before income tax expense		(6,504	)			(4,965	)			(20,283	)			(15,624	)
Income tax expense		—				—				—				—
Net loss	$	(6,504	)		$	(4,965	)		$	(20,283	)		$	(15,624	)
Net loss per share, basic and diluted	$	(0.31	)		$	(0.28	)		$	(1.01	)		$	(0.88	)
Weighted average number of common shares outstanding, basic and diluted		21,052				17,878				20,070				17,706

Eton Pharmaceuticals, Inc.
Condensed Balance Sheets
(in thousands, except share and per share amounts)

	September 30, 2020				December 31, 2019
	(Unaudited)
Assets
Current assets:
Cash and cash equivalents	$	7,332			$	12,066
Accounts receivable, net		—				473
Inventory		1,699				380
Prepaid expenses and other current assets		754				2,090
Total current assets		9,785				15,009
Property and equipment, net		854				1,117
Intangible assets, net		612				725
Operating lease right-of-use assets, net		63				160
Other long-term assets, net		81				61
Total assets	$	11,395			$	17,072
Liabilities and stockholders’ equity
Current liabilities:
Accounts payable	$	2,208			$	575
PPP loan, current portion		219				—
Accrued liabilities		792				1,388
Total current liabilities		3,219				1,963
Long-term debt, net of discount and including accrued fees		6,496				4,540
Long-term portion of PPP and EIDL loans		292				—
Operating lease liabilities, net of current portion		—				19
Total liabilities		10,007				6,522
Commitments and contingencies (Note 11)
Stockholders’ equity
Common stock, $0.001 par value; 50,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 20,988,533 and 17,877,486 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively		21				18
Additional paid-in capital		85,838				74,720
Accumulated deficit		(84,471	)			(64,188	)
Total stockholders’ equity		1,388				10,550
Total liabilities and stockholders’ equity	$	11,395			$	17,072

Eton Pharmaceuticals, Inc.
Condensed Statements of Cash Flows
(In thousands)
(Unaudited)

	Nine months ended September 30, 2020				Nine months ended  September 30, 2019
Cash flows from operating activities
Net loss	$	(20,283	)		$	(15,624	)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation		1,803				1,387
Common stock issued for product candidate licensing rights		1,264				—
Depreciation and amortization		490				299
Debt discount amortization		85				—
Changes in operating assets and liabilities:
Accounts receivable		473				—
Inventory		(1,319	)			—
Prepaid expenses and other assets		1,305				426
Accounts payable		1,633				(403	)
Accrued liabilities		(615	)			(263	)
Net cash used in operating activities		(15,164	)			(14,178	)
Cash used in investing activities
Purchases of property and equipment		(6	)			(1,062	)
Cash flows from financing activities
Proceeds from issuance of long-term debt, net of issuance costs		1,965				—
Proceeds from sales of common stock, net of offering costs		7,756				—
Proceeds from PPP and EIDL loans		511				—
Proceeds from employee stock purchase plan and stock option exercises		204				282
Net cash provided by financing activities		10,436				282
Change in cash and cash equivalents		(4,734	)			(14,958	)
Cash and cash equivalents at beginning of period		12,066				26,735
Cash and cash equivalents at end of period	$	7,332			$	11,177
Supplemental disclosures of cash flow information
Cash paid for interest	$	545			$	—
Cash paid for income taxes	$	—			$	—
Supplemental disclosure of non-cash financing activity
Relative fair value of common stock warrants issued in connection with debt	$	94			$	—

Investor Contact:
David Krempa
dkrempa@etonpharma.com
612-387-3740

FAQ

What are the key financial results for Eton Pharmaceuticals in Q3 2020?

Eton Pharmaceuticals reported a revenue of ($0.2) million, with a net loss of $6.5 million for Q3 2020.

What is the status of ALKINDI SPRINKLE?

ALKINDI SPRINKLE received FDA approval and is expected to be commercially available by the end of November 2020.

What upcoming events should investors watch for Eton Pharmaceuticals?

Investors should note the PDUFA dates for submitted NDAs, scheduled for May 27, May 29, and June 18, 2021.

How much funding did Eton Pharmaceuticals raise recently?

Eton Pharmaceuticals raised approximately $22.5 million through an oversubscribed equity offering.

What were Eton Pharmaceuticals' R&D expenses for Q3 2020?

R&D expenses were reported at $2.8 million for the third quarter of 2020.